联系人 Mr. Orchard W
100 N Howard ST STE R, Spokane, Washington 99201, USA, USA, Los Angeles, California
Bamlanivimab (LY-CoV**5) is a neutralising monoclonal antibody
intended for the treatment of mild to moderate COVID**9.
Drug Name
Bamlanivimab (LY-CoV**5)
Developer
Eli Lilly and Company
Therapy Class
Neutralising monoclonal antibody
Current Indication
Mild to moderate COVID**9
Market Sector
Infectious diseases
Development Status
US FDAs emergency use authorisation (EUA)
Bamlanivimab (LY-CoV**5) received emergency use
authorisation for the treatment of mild to moderate COVID**9 in
high-risk patients in November ***0. Credit: Eli Lilly and
Company.
| 国家: | USA |
| 型号: | - |
| 离岸价格: | 获取最新报价 |
| 位置: | - |
| 最小订单价格: | - |
| 最小订单: | 50 Unit |
| 包装细节: | - |
| 交货时间: | - |
| 供应能力: | 300 Unit per Week |
| 付款方式: | - |
| 產品組 : | - |
